Hypopituitarism (Panhypopituitarism) Treatment & Management
- Author: Bernard Corenblum, MD, FRCP(C); Chief Editor: George T Griffing, MD more...
Approach Considerations
Missed or delayed diagnosis of hypopituitarism could potentially lead to permanent disability or death. Medical care consists of hormone replacement as appropriate and treatment of the underlying cause. Glucocorticoids are required if the ACTH-adrenal axis is impaired. This is particularly important in sudden collapse due to pituitary apoplexy or acute obstetric hemorrhage with pituitary insufficiency. In such circumstances, do not delay initiation of a possibly life-saving treatment pending a definitive diagnosis. Treat secondary hypothyroidism with thyroid hormone replacement.
Treat gonadotropin deficiency with sex-appropriate hormones. In men, testosterone replacement is used and substituted with HCG injections if the patient desires fertility. In women, estrogen replacement is used with or without progesterone as appropriate.
GH is replaced in children as appropriate. GH is not routinely replaced in adults unless the patient is symptomatic of GH deficiency, after all other pituitary hormones have been replaced. Then, a 6-month trial of replacement GH therapy may be considered.
Surgical care depends on the underlying cause and severity of hypopituitarism. In pituitary apoplexy, prompt surgical decompression may be life saving if head imaging reveals clinically significant tumor mass effect. Microadenomas do not need surgical treatment, unless GH or ACTH hypersecretion is present. Prolactinomas, small and large, generally respond to medical therapy with tumor shrinkage and alleviation of mass symptoms. Debulk macroadenomas with mass symptoms that that do not respond to medical therapy or are not expected to respond to medical therapy. Some asymptomatic nonsecreting macroadenomas may have an option of close clinical/radiological observation. If radiotherapy is used, long-term new-onset hypopituitarism may occur and must be monitored.
In very ill hospitalized patients or in patients undergoing major procedures, stress-dose steroids are required and are quickly tapered to a maintenance schedule after the procedure. Minor procedures or illnesses may not necessitate a change in steroid dose or may require a simple doubling of the usual daily dose until the illness resolves. Other hormone replacements are continued at their usual maintenance doses as appropriate.
No special diet is necessary in patients with hypopituitarism unless dictated by an underlying disease process. Also, no activity restrictions are necessary unless dictated by an underlying disease process. Include an endocrinologist, a neurosurgeon, and a radiologist in consultations, as appropriate.
Deterrence/prevention
Good obstetric care has reduced the incidence of postpartum hypopituitarism. Radiation therapy that minimizes exposure of the pituitary reduces the time of onset of hypopituitarism.[5] Experienced neurosurgeons employing high-resolution microscopic hypophyseal surgery may reduce the likelihood of subsequent hypopituitarism.
Follow-up care
Provide long-term follow-up care for complications of underreplacement or overreplacement. Stressful situations warrant an adjustment in therapy. Unlike adults, children require GH replacement.
Follow-up care also involves adjusting hormone replacement to physiologic maintenance levels using the lowest dose. Monitor the patient to avoid overreplacement. The incidence of new neoplasms is increased in young people treated with growth hormone who had previous tumor treatment.[14] This does not appear to be the case in adult patients. Excessive glucocorticoid or thyroid doses, or inadequate sex steroid doses, have been associated with decreased bone mineral density.
Schneider HJ, Schneider M, Saller B, et al. Prevalence of anterior pituitary insufficiency 3 and 12 months after traumatic brain injury. Eur J Endocrinol. Feb 2006;154(2):259-65. [Medline].
Kokshoorn NE, Smit JW, Nieuwlaat WA, et al. Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study. Eur J Endocrinol. Aug 2011;165(2):225-31. [Medline].
Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab. Aug 2011;96(8):2330-40. [Medline]. [Full Text].
Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA. Radiation-induced hypopituitarism. Endocr Relat Cancer. Sep 2009;16(3):733-72. [Medline].
Castinetti F, Régis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol. Apr 2010;6(4):214-23. [Medline].
de Graaff LC, De Bellis A, Bellastella A, et al. Antipituitary antibodies in dutch patients with idiopathic hypopituitarism. Horm Res. Jan 2009;71(1):22-7. [Medline].
Fatemi N, Dusick JR, Mattozo C, et al. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery. Oct 2008;63(4):709-18; discussion 718-9. [Medline].
Regal M, Páramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf). Dec 2001;55(6):735-40. [Medline].
Clayton RN. Mortality, cardiovascular events and risk factors in hypopituitarism. Growth Horm IGF Res. Feb 1998;8 Suppl A:69-76. [Medline].
Bulow B, Hagmar L, Eskilsson J, Erfurth EM. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab. Feb 2000;85(2):574-84. [Medline].
Nakamoto J. Laboratory diagnosis of multiple pituitary hormone deficiencies: issues with testing of the growth and thyroid axes. Pediatr Endocrinol Rev. Jan 2009;6 Suppl 2:291-7. [Medline].
Li G, Shao P, Sun X, Wang Q, Zhang L. Magnetic resonance imaging and pituitary function in children with panhypopituitarism. Horm Res Paediatr. 2010;73(3):205-9. [Medline].
Dutta P, Bhansali A, Singh P, et al. Congenital hypopituitarism: clinico-radiological correlation. J Pediatr Endocrinol Metab. Oct 2009;22(10):921-8. [Medline].
Child CJ, Zimmermann AG, Woodmansee WW, et al. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol. Aug 2011;165(2):217-223. [Medline]. [Full Text].
Harsch IA, Schuller A, Hahn EG, Hensen J. Cortisone replacement therapy in endocrine disorders - quality of self-care. J Eval Clin Pract. Jun 2010;16(3):492-8. [Medline].

